InventisBio of Shanghai Raises $19 Million from OrbiMed and Lilly

InventisBio, a Shanghai-US startup, raised $19 million in a Series B round for its portfolio of four small molecule candidates. The two-year-old company is targeting cancer (lung and breast) and gout indications, developing molecules that might be paired with immuno-oncology therapies. It hopes to start clinical trials on three of the candidates in the US and China this year. The investment was led by OrbiMed Asia Partners and joined by Lilly Asia Ventures. More details.... Share this with colleagues: // //